BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round


2/3/2010 8:09:48 AM

Bookmark and Share

GENEVA, February 3 /PRNewswire/ -- Viroblock SA, a start-up dedicated to developing and commercializing a new generation of anti-viral products, today announced that Dr. Jamie Paterson will join Viroblock as Chief Executive Officer (CEO).

Jamie Paterson, a British national, can look back at 20 years of experience in the pharmaceutical industry. Prior to joining Viroblock he was Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at Procter & Gamble he held several positions with increasing responsibility including Marketing Manager Italy and Commercial Director Spain. His final position at P&G was European Director of Strategic Planning and New Business Development - Rx & OTC. Jamie holds a PhD in Biochemistry from Imperial College, University of London.

"I welcome Jamie as our new CEO and I am pleased to concentrate my activities to further demonstrate scientifically the potential of our technology in several viral indications" said Thierry Pelet who is one the co-founders of the company. Thierry will assume the position of Chief Science Officer (CSO).

Viroblock further announced that it has completed its second round of equity funding. The Series B financing round was led by Fongit Seed Invest SA. Peter Pfister, Initiative Capital Romandie SA (managed by DEFI Gestion) and BlueOcean Ventures acted as co-investors.

"With Jamie and Thierry we have a strong leadership team with proven business skills and accomplished scientific know-how. This team equipped with the additional funding can now start developing our first anti-viral products, which will bring the company to the next level, said Peter Pfister, Chairman of the Board.

About Viroblock

Viroblock is dedicated to developing and commercializing a new generation of anti-viral products with a novel mechanism of action against enveloped viruses. Enveloped viruses represent more than 60% of all existing viruses and include major human pathogens such as human and avian influenzas, the hepatitis B and C viruses and the AIDS virus.

Viroblock's unique proprietary products and technologies open very promising opportunities in a number of prophylactic and therapeutic applications.

Viroblock was founded in October 2005 by the late Donald Wallach, a scientist and academic with past tenure at the Harvard Medical School and Tufts University, and a pioneer in the research of liposome systems.

For more information:

Thierry Pelet +41-22-884-8344 info@viroblock.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES